All In MedTech

FDA Clearance Tracker · P850048-S060

Access Hybritech PSA

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 4, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 4, 2024

Approved

Time to decision

160 days

Received Mar 28, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P850048-S060
Device name
Access Hybritech PSA
Applicant location
Brea, CA
Received
Mar 28, 2024
Decided
Sep 4, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P850048

Device type

Device class
Class III

Every decision under product code MTF

FDA's approval statement

As written in FDA's record.

Migration of the Access Hybritech PSA to the DxI 9000 Access Immunoassay Analyzer.

Source documents

Other decisions for Beckman Coulter, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.